Restricted replication of the live attenuated influenza A virus vaccine during infection of primary differentiated human nasal epithelial cells

Vaccine

Volumn 33, Issue 36, 2015, Pages 4495-4504

  Fischer, William A ^a,d   King, Landon S ^a   Lane, Andrew P ^b   Pekosz, Andrew ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Molecular Biology and Genetics ^*  (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Influenza; Live attenuated influenza vaccine; Nasal epithelial cells

Indexed keywords

INFLUENZA VACCINE; VIRUS PROTEIN; CULTURE MEDIUM; LIVE VACCINE; VIRUS ANTIGEN;

ARTICLE; BLOOD CELL; CELL CULTURE; CONTROLLED STUDY; ENDOSCOPIC SINUS SURGERY; EPITHELIUM CELL; FLUORESCENCE MICROSCOPY; HEMAGGLUTINATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; INFLUENZA A; INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; MDCK CELL LINE; PHENOTYPE; PRIORITY JOURNAL; SEASONAL INFLUENZA; VIRUS REPLICATION; WESTERN BLOTTING; WILD TYPE; ANIMAL; CHEMISTRY; CULTURE MEDIUM; CYTOLOGY; DOG; INFLUENZA A VIRUS; NOSE MUCOSA; PHYSIOLOGY; TEMPERATURE; VIROLOGY; VIRUS LOAD;

ANIMALS; ANTIGENS, VIRAL; CELLS, CULTURED; CULTURE MEDIA; DOGS; EPITHELIAL CELLS; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; NASAL MUCOSA; TEMPERATURE; VACCINES, ATTENUATED; VIRAL LOAD; VIRUS REPLICATION;

EID: 84939565839     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.07.023     Document Type: Article

References (35)

1. Fischer W.A., Hayden F. Novel Antiviral Agents and Approaches in Pandemic Influenza. National Institute of Allergy and Infectious Diseases, NIH, Frontiers in Research 2008, 179-192. Humana Press, New York. V. St. Georgiev, K.A. Western, J.J. McGowan (Eds.).
2. Maassab H.F. Adaptation and growth characteristics of influenza virus at 25 degrees C. Nature 1967, 213:612-614.
3. Murphy B.R., Coelingh K. Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Viral Immunol 2002, 15:295-323.
4. Isakova-Sivak I., Chen L.-M., Matsuoka Y., Voeten J.T.M., Kiseleva I., Heldens J.G.M., et al. Genetic bases of the temperature-sensitive phenotype of a master donor virus used in live attenuated influenza vaccines: a/Leningrad/134/17/57 (H2N2). Virology 2011, 412:297-305.
5. Chan W., Zhou H., Kemble G., Jin H. The cold adapted and temperature sensitive influenza A/Ann Arbor/6/60 virus, the master donor virus for live attenuated influenza vaccines, has multiple defects in replication at the restrictive temperature. Virology 2008, 380:304-311.
6. Jin H., Bin L., Zhou H., Kemble G. Genetic studies of Flumist influenza vaccines derived from cold-adapted A/Ann Arbor/6/60. Int Congr Ser 2004, 1263:153-156.
7. Jin H., Lu B., Zhou H., Ma C., Zhao J., Yang C.F., et al. Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (FluMist) derived from cold-adapted A/Ann Arbor/6/60. Virology 2003, 306:18-24.
8. Snyder M.H., Betts R.F., DeBorde D., Tierney E.L., Clements M.L., Herrington D., et al. Four viral genes independently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccines. J Virol 1988, 62:488-495.
9. Snyder M.H., Clements M.L., De Borde D., Maassab H.F., Murphy B.R. Attenuation of wild-type human influenza A virus by acquisition of the PA polymerase and matrix protein genes of influenza A/Ann Arbor/6/60 cold-adapted donor virus. J Clin Microbiol 1985, 22:719-725.
10. Odagiri T., Tanaka T., Tobita K. Temperature-sensitive defect of influenza A/Ann Arbor/6/60 cold-adapted variant leads to a blockage of matrix polypeptide incorporation into the plasma membrane of the infected cells. Virus Res 1987, 7:203-218.
11. Husseini R.H., Sweet C., Collie M.H., Smith H. Elevation of nasal viral levels by suppression of fever in ferrets infected with influenza viruses of differing virulence. J Infect Dis 1982, 145:520-524.
12. Rappuoli RaDG G. Influenza vaccines for the future. Birkhauser advances in infectious diseases 2010, Springer, Italy. 2nd ed. A. Schmidt, O. Weber, S.H.E. Kaufmann (Eds.).
13. Lane A.P., Saatian B., Yu X.Y., Spannhake E.W. mRNA for genes associated with antigen presentation are expressed by human middle meatal epithelial cells in culture. Laryngoscope 2004, 114:1827-1832.
14. Ramanathan M., Lane A.P. Innate immunity of the sinonasal cavity and its role in chronic rhinosinusitis. Otolaryngol Head Neck Surg 2007, 136:348-356.
15. Ramanathan M., Lee W.K., Dubin M.G., Lin S., Spannhake E.W., Lane A.P. Sinonasal epithelial cell expression of toll-like receptor 9 is decreased in chronic rhinosinusitis with polyps. Am J Rhinol 2007, 21:110-116.
16. McCown M.F., Pekosz A. The influenza A virus M2 cytoplasmic tail is required for infectious virus production and efficient genome packaging. J Virol 2005, 79:3595-3605.
17. Newby C.M., Rowe R.K., Pekosz A. Influenza A virus infection of primary differentiated airway epithelial cell cultures derived from Syrian golden hamsters. Virology 2006, 354:80-90.
18. Grantham M.L., Wu W.H., Lalime E.N., Lorenzo M.E., Klein S.L., Pekosz A. Palmitoylation of the influenza A virus M2 protein is not required for virus replication in vitro but contributes to virus virulence. J Virol 2009, 83:8655-8661.
19. Zebedee S.L., Lamb R.A. Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol 1988, 62:2762-2772.
20. Yewdell J.W., Frank E., Gerhard W. Expression of influenza A virus internal antigens on the surface of infected P815 cells. J Immunol 1981, 126:1814-1819.
21. Kiseleva I., Klimov A., Su Q., Szymkowiak C., Toner T.J., Kwan W.-S., et al. Role of individual genes of A/Leningrad/134/17/57 (H2N2) cold-adapted donor strain in manifestation of the temperature-sensitive phenotype or reassortant influenza A viruses. Int Congr Ser 2004, 1623:547-550.
22. Stewart S.M., Wu W-H., Lalime E.N., Pekosz A. The cholesterol recognition/interaction amino acid consensus motif of the influenza A virus M2 protein is not required for virus replication but contributes to virulence. Virology 2010, 405:530-538.
23. Grantham M.L., Stewart S.M., Lalime E.N., Pekosz A. Tyrosines in the influenza A virus M2 protein cytoplasmic tail are critical for production of infectious virus particles. J Virol 2010, 84:8765-8776.
24. Fischer W.A., Chason K.D., Brighton M., Jaspers I. Live attenuated influenza vaccine strains elicit a greater innate immune response than antigenically-matched seasonal influenza viruses during infection of human nasal epithelial cell cultures. Vaccine 2014, 32:1761-1767.
25. Ilyushina N.A., Ikizler M.R., Kawaoka Y., Rudenko L.G., Treanor J.J., Subbarao K., et al. Comparative study of influenza virus replication in MDCK cells and in primary cells derived from adenoids and airway epithelium. J Virol 2012, 86:11725-11734.
26. Chen B.J., Leser G.P., Morita E., Lamb R.A. Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles. J Virol 2007, 81:7111-7123.
27. Marsh G.A., Hatami R., Palese P. Specific residues of the influenza A virus hemagglutinin viral RNA are important for efficient packaging into budding virions. J Virol 2007, 81:9727-9736.
28. Molinari N.A., Ortega-Sanchez I.R., Messonnier M.L., Thompson W.W., Wortley P.M., Weintraub E., et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007, 25:5086-5096.
29. Ashkenazi S., Vertruyen A., Aristegui J., Esposito S., McKeith D.D., Klemola T., et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006, 25:870-879.
30. Belshe R.B., Ambrose C.S., Yi T. Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age. Vaccine 2008, 26(Suppl 4):D10-D16.
31. Belshe R.B., Edwards K.M., Vesikari T., Black S.V., Walker R.E., Hultquist M., et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007, 356:685-696.
32. Bridges C.B., Thompson W.W., Meltzer M.I., Reeve G.R., Talamonti W.J., Cox N.J., et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA 2000, 284:1655-1663.
33. Fleming D.M., Crovari P., Wahn U., Klemola T., Schlesinger Y., Langussis A., et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2006, 25:860-869.
34. Halloran M.E., Piedra P.A., Longini I.M., Gaglani M.J., Schmotzer B., Fewlass C., et al. Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004. Vaccine 2007, 25:4038-4045.
35. Jefferson T., Rivetti A., Harnden A., Di Pietrantonj C., Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2008, 16(2):CD004879.